Compare Organon & Co. Common Stock (OGN) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Omnicom Group Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Omnicom Group Inc. trades at $78.84 (market cap $21.53B). The key difference: Omnicom Group Inc. is far larger — about 5.9× Organon & Co. Common Stock's market cap, and Omnicom Group Inc. pays the higher dividend (4.08%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Omnicom Group Inc. for 64 Days on average.
| OGN | OMC | |
|---|---|---|
Market Cap | $3.62B | $21.53B |
Volume | 2,892,999 | 2,515,610 |
Sector | Health | Media |
52-Week High | $13.81 | $88.94 |
52-Week Low | $5.70 | $67.27 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.04B | $29.61B |
Dividend Yield | 0.58% | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Omnicom Group (OMC) trades at $78.41, up 1.74% with a bullish technical signal despite mixed earnings results. The company shows strong revenue growth to $17.27B in 2025 but reported a net loss of -$54.50M. Analyst consensus is mixed with 32% buy ratings and a $100.50 price target, while recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings.
OMC presents a value opportunity with attractive P/S of 0.88 and dividend yield, though high P/E of 212.14 reflects earnings volatility. Key risks include advertising market weakness and elevated debt levels, while AI capabilities and post-Interpublic synergies offer growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
